Seaport Therapeutics, Inc. (NASDAQ:SPTX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the thirteen analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $37.12.
Several research analysts have commented on the company. Weiss Ratings upgraded Seaport Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, November 4th. JPMorgan Chase & Co. upped their target price on Seaport Therapeutics from $40.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, November 5th. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Seaport Therapeutics in a research report on Thursday, October 8th. Raymond James Financial started coverage on Seaport Therapeutics in a research note on Friday, September 25th. They set a “strong-buy” rating and a $46.00 price target on the stock. Finally, Seaport Research Partners set a $28.00 price target on Seaport Therapeutics in a research note on Wednesday, October 14th.
Read Our Latest Report on SPTX
Seaport Therapeutics Trading Down 4.3%
NASDAQ SPTX opened at $19.12 on Tuesday. The business has a 50-day moving average of $20.26. The company has a market capitalization of $1.02 billion and a PE ratio of -1.52. Seaport Therapeutics has a 12 month low of $14.85 and a 12 month high of $28.38.
Seaport Therapeutics (NASDAQ:SPTX – Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.09. Research analysts forecast that Seaport Therapeutics will post -4.30 earnings per share for the current year.
Insiders Place Their Bets
In other Seaport Therapeutics news, Director Denice Torres bought 5,000 shares of the company’s stock in a transaction on Tuesday, November 3rd. The shares were bought at an average cost of $19.86 per share, for a total transaction of $99,300.00. Following the acquisition, the director directly owned 5,000 shares in the company, valued at approximately $99,300. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the business. Alps Advisors Inc. lifted its position in shares of Seaport Therapeutics by 30.5% in the 3rd quarter. Alps Advisors Inc. now owns 70,921 shares of the company’s stock worth $1,430,000 after purchasing an additional 16,593 shares during the period. HighTower Advisors LLC bought a new position in shares of Seaport Therapeutics during the second quarter valued at approximately $362,000. Squarepoint Ops LLC bought a new position in shares of Seaport Therapeutics during the second quarter valued at approximately $538,000. State Street Corp purchased a new position in Seaport Therapeutics during the second quarter valued at approximately $1,448,000. Finally, Alyeska Investment Group L.P. purchased a new position in Seaport Therapeutics during the second quarter valued at approximately $1,629,000.
About Seaport Therapeutics
Seaport Therapeutics is a clinical-stage biopharmaceutical company developing medicines for neuropsychiatric disorders. The company uses its Glyph platform to design oral prodrugs intended to improve the delivery of therapies that can be difficult to administer or absorb by mouth. Its pipeline includes SPT-300, an oral prodrug of allopregnanolone being developed for depression. Seaport was launched in 2024 and is headquartered in Boston, Massachusetts. Its leadership includes founder and Chief Executive Officer Daphne Zohar.
Recommended Stories
- Five stocks we like better than Seaport Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Seaport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seaport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
